RxDoctor Payments Data

Allan Turner, MD

Nephrology · Greenwood, SCNPI 1396701710

Payments from drug & device makers

$1,778in general payments, 2019–2025

Across 67 payments — averaging $26.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$333
  • Aurinia Pharma U.S., Inc.$255
  • Mallinckrodt Enterprises LLC$185
  • AstraZeneca$155
  • Vifor Pharma, Inc.$154
  • Travere Therapeutics, Inc.$139
  • plus $557 from 12 others

What the payments were for

  • Food & beverage$1,51985%
  • Education$25915%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,778 in reported general payments places this provider in the 45th percentile of 180 nephrology providers in South Carolina.

See all nephrology providers in South Carolina

Medicare billing

Part B allowed, 2024
$203,900
Medicare patients
396
Services billed
2,274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol122$104,466
JardianceEmpagliflozin109$83,808
RayaldeeCalcifediol28$45,146
KerendiaFinerenone55$41,649
VeltassaPatiromer Calcium Sorbitex21$19,317
Sevelamer Carbonate42$5,852
Calcitriol269$4,814
SpsSodium Polystyrene Sulfon/Sorb14$4,141
Allopurinol228$3,017
Bumetanide76$2,747
ProsolParenteral Amino Acid 20% No.117$2,624
Febuxostat25$2,599
Calcium Acetate35$2,433
Potassium Chloride69$2,021
Cinacalcet Hcl40$1,949

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$155$104,466122 claims
Boehringer IngelheimJardiance$15$83,808109 claims
BayerKerendia$75$41,64955 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 180 nephrology providers in South Carolina.

Other nephrology in Greenwood

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →